Confirm diagnosis via recent MRI/CT imaging. Perform coagulation profile and platelet count. Ensure informed consent is signed. Administer prophylactic antibiotics if indicated. Position patient and perform site marking.
Patient to remain in prone or supine position for 30 minutes post-procedure. Monitor vital signs for 1 hour. Assess for neurological deficit. Instruct patient to avoid heavy lifting for 48 hours. Discharge once stable. Analgesia as needed.
Introduction: Stabilizing the Oncologic Spine
Vertebral compression fractures (VCFs) resulting from metastatic disease or multiple myeloma represent a significant source of morbidity for cancer patients. Unlike osteoporotic fractures, pathologic oncologic fractures are characterized by aggressive bone destruction, compromised structural integrity, and the potential for epidural extension. Percutaneous Vertebral Augmentation (PVA)—encompassing both Vertebroplasty (VP) and Kyphoplasty (KP)—has evolved into the gold standard for minimally invasive palliative care in oncology.
These procedures are designed to provide immediate mechanical stabilization, facilitate rapid pain relief, and allow for the resumption of systemic oncologic therapies (chemotherapy or radiation) that might otherwise be delayed by debilitating spinal pain. This guide provides an exhaustive clinical overview of these procedures, intended for clinical practitioners and medical professionals.
Technical Specifications and Mechanisms of Action
The fundamental goal of PVA is the stabilization of the vertebral body through the injection of polymethylmethacrylate (PMMA) or other bone cements.
Vertebroplasty (VP)
- Mechanism: Direct, low-pressure injection of high-viscosity cement into the cancellous bone of the fractured vertebra.
- Primary Benefit: Rapid stabilization and analgesia via thermal necrosis of nociceptors and mechanical reinforcement.
- Technical Constraint: Limited ability to restore vertebral height; higher risk of cement extravasation due to lower viscosity requirements.
Kyphoplasty (KP)
- Mechanism: A balloon tamp is inserted into the vertebral body and inflated to create a void, which is then filled with bone cement under controlled pressure.
- Primary Benefit: Restoration of vertebral height and reduction of kyphotic deformity.
- Technical Constraint: More invasive than VP; requires larger access cannulas and carries a higher cost profile.
| Feature | Vertebroplasty (VP) | Kyphoplasty (KP) |
|---|---|---|
| Height Restoration | Minimal | Significant |
| Cement Pressure | Low (Gravity/Syringe) | Controlled (High Pressure) |
| Procedure Time | Shorter | Longer |
| Primary Indication | Painful, stable fractures | Fractures with deformity/collapse |
Clinical Indications and Patient Selection
The decision to perform PVA in an oncologic patient requires a multidisciplinary approach involving orthopedics, interventional radiology, and oncology.
Indications
- Refractory Pain: Pain that is unresponsive to analgesics, including opioid therapy.
- Mechanical Instability: Radiographic evidence of cortical breach or progressive collapse.
- Anticipated Systemic Therapy: To restore mobility so the patient can tolerate radiation or chemotherapy positioning.
- Prophylactic Augmentation: Patients with extensive lytic lesions at risk of imminent collapse.
Clinical Contraindications
- Absolute: Active systemic infection, uncorrectable coagulopathy, or complete spinal cord compression with neurological deficit.
- Relative: Posterior cortical wall breach (high risk of epidural leakage), extreme vertebral collapse (vertebra plana), or extensive epidural tumor burden.
Pre-Operative Preparation and Assessment
Success in oncologic PVA is predicated on rigorous imaging and patient optimization.
1. Imaging Requirements
- MRI (T1/T2/STIR): Mandatory to assess the acuity of the fracture and determine if there is epidural tumor extension or cord compression.
- CT Scan: Essential for assessing the integrity of the posterior vertebral wall and the pedicles.
- PET-CT: Often utilized to determine overall metabolic activity and the presence of other metastatic sites.
2. Patient Optimization
- Coagulation Profile: Patients on anticoagulants must be bridged; platelet count should generally be >50,000/μL.
- Pain Management: Pre-procedure stabilization of pain to allow for prone positioning on the fluoroscopy table.
- Prophylactic Antibiotics: Standard protocols (e.g., Cefazolin) are utilized to prevent discitis or osteomyelitis.
The Procedural Workflow
The procedure is typically performed under conscious sedation or general anesthesia, depending on the patient's ability to tolerate the prone position.
Step-by-Step Execution
- Positioning: Patient is placed prone on a radiolucent table with chest and pelvic bolsters to allow for potential spinal decompression.
- Access: Transpedicular or extrapedicular approach under biplanar fluoroscopic guidance.
- Cannula Placement: A bone biopsy needle is advanced into the vertebral body. In oncology cases, a biopsy is almost always taken before cement injection to confirm the diagnosis.
- Cavity Creation (Kyphoplasty only): The balloon is inflated, monitoring for cortical wall integrity.
- Cement Injection: PMMA cement (often mixed with barium or tantalum for radiopacity) is injected under real-time fluoroscopic visualization.
- Termination: Injection is halted immediately upon the first sign of venous or epidural extravasation.
Post-Operative Recovery and Outcomes
Immediate Post-Op
- Recovery: Most patients are mobilized within 1–2 hours.
- Analgesia: Significant reduction in pain is reported by 80–90% of patients within 24 hours.
- Follow-up: Clinical evaluation for neurological symptoms is mandatory during the first 6–12 hours.
Expected Outcomes
- Pain Reduction: Marked decrease in Visual Analog Scale (VAS) scores.
- Functional Mobility: Improvement in Oswestry Disability Index (ODI) scores.
- Oncologic Synergy: Ability to discontinue high-dose opioids and transition to standard systemic oncology management.
Risks and Complications
While PVA is minimally invasive, the oncologic population is inherently higher risk.
- Cement Extravasation: The most common complication. Can occur into the venous system (pulmonary embolism), the spinal canal (nerve root compression), or the disc space.
- Infection: Discitis or osteomyelitis.
- Adjacent Level Fractures: The "stiffening" of the augmented vertebra may increase stress on adjacent segments, leading to new fractures.
- Thermal Injury: Exothermic reaction of PMMA potentially damaging neural structures.
Alternative Treatments
When PVA is contraindicated or insufficient, alternative modalities include:
- Radiofrequency Ablation (RFA): Used in conjunction with cement to debulk tumor tissue prior to augmentation.
- Spinal Stabilization/Instrumentation: Open surgery with pedicle screws and rods for patients with severe mechanical instability or neurological deficit.
- Stereotactic Radiosurgery (SRS): High-dose, focal radiation to control tumor growth within the vertebral body.
- Bisphosphonates/RANK-Ligand Inhibitors: Pharmacological management to reduce bone turnover and fracture risk.
Frequently Asked Questions (FAQ)
1. How is a pathologic fracture different from an osteoporotic fracture?
Pathologic fractures are caused by malignant infiltration. They are often more aggressive, involve soft tissue masses, and may be associated with spinal cord compression.
2. Can I have radiation therapy after Vertebroplasty?
Yes. In fact, Vertebroplasty often makes it easier for patients to lie flat for the duration of their radiation therapy.
3. What is the success rate for pain relief?
Clinical studies indicate a success rate for significant pain reduction between 85% and 95% in appropriately selected patients.
4. Is the biopsy performed during the procedure safe?
Yes, taking a biopsy via the same cannula used for cement injection is standard practice and does not significantly increase the risk profile.
5. How long does the cement stay in the spine?
The PMMA cement is permanent. It does not resorb and remains a structural component of the vertebral body for the patient’s lifetime.
6. What if the cancer has already spread to the spinal canal?
If there is significant epidural tumor mass causing compression, PVA is generally contraindicated, and surgical decompression is preferred.
7. Does the procedure cure the cancer?
No. Vertebroplasty and Kyphoplasty are purely palliative, localized treatments designed to stabilize bone and reduce pain.
8. Will I need physical therapy after the procedure?
Physical therapy is highly recommended to improve core strength and gait, preventing further falls and secondary fractures.
9. What is the risk of a pulmonary embolism from cement?
The risk is low (<1–2%) when performed by experienced operators using real-time fluoroscopy and high-viscosity cement.
10. Can I have this procedure done on multiple vertebrae?
Yes, "multilevel augmentation" is common in patients with multiple myeloma or widespread metastatic disease, though it may be staged over several sessions to reduce anesthesia time.
Conclusion
Kyphoplasty and Vertebroplasty for pathologic oncologic fractures represent a vital intersection of interventional orthopedics and oncology. By providing rapid stabilization and pain relief, these procedures serve as a bridge, allowing cancer patients to pursue life-extending therapies with improved quality of life. As technology advances—particularly with the integration of RFA and newer, more biocompatible cements—the role of PVA in the oncologic toolkit will continue to expand. Practitioners must remain vigilant regarding patient selection and meticulous in their procedural technique to ensure the best possible clinical outcomes.
